ecrin-mdr-crcClinical2015Colorectal cancerColorectal NeoplasmsColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2191654Brazil7RegorafenibECRIN MDRCompletedfalseRegorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal CancerTo determine the efficacy (as measured by progression-free survival [PFS] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never exposed to antiangiogenic therapy.2015-07-152191654NCT02465502